Concomitant anti–tumor necrosis factor and anti–interleukin 17 therapy in severe, refractory hidradenitis suppurativa: A case series

Estella Bastian, Lia Bizuneh, Erin H Amerson, Haley B Naik · 2026

Read Concomitant anti–tumor necrosis factor and anti–interleukin 17 therapy in severe, refractory hidradenitis suppurativa: A case series by Estella Bastian, Lia Bizuneh, Erin H Amerson, Haley B Naik (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13634981.txt.

Description

Hidradenitis suppurativa is a painful skin disease of boils and tunnels, and single biologic drugs help only about half of patients. Estella Bastian, Lia Bizuneh, Erin Amerson, and Haley Naik reviewed in 2026 what happened when eleven patients took two biologics at once. The pair blocked two different immune signals. All eleven had stubborn, severe disease and had failed several single drugs first.

The patients were mostly women, with disease lasting a median of eleven years across about five body sites. The report gathers their doctor-rated severity scores, patient reports, and side effects from chart review between 2022 and 2025. The authors frame dual therapy as a promising route for refractory cases, while the small, backward-looking design limits firm claims about benefit and safety.

Catalog record

CREATOREstella Bastian, Lia Bizuneh, Erin H Amerson, Haley B Naik
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE9 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13634981

Browse the full library · About the Tower of Babel